



## REGENXBIO to Participate in Upcoming Investor Conferences

November 2, 2022 11:05 AM EDT

ROCKVILLE, Md., Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

**Credit Suisse 31st Annual Healthcare Conference**

**Date:** Tuesday, November 8, 2022

**Location:** Terranea Resort, Rancho Palos Verdes, CA

**Barclays Sixth Annual Barclays Gene Editing/Therapy Summit**

**Date:** November 14, 2022

**Panel Title:** AAV Gene Therapy – Current Status and Future Direction

**Panel Time:** 2:50 p.m. ET

**About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

**Contacts:**

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

Investors:  
Chris Brinzey, ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301665884.html>

SOURCE REGENXBIO Inc.